Literature DB >> 22110176

Comment on: Hermida et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011;34:1270-1276.

Niklas B Rossen, Klavs W Hansen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22110176      PMCID: PMC3220867          DOI: 10.2337/dc11-1514

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
Hermida et al. (1) have recently shown an impressive reduction of asleep blood pressure and associated reduction of cardiovascular disease (CVD) events in type 2 diabetic patients treated with at least one antihypertensive drug at bedtime compared with patients who ingested all drugs in the morning. This is a subgroup analysis of the diabetic patients (20%) enrolled in the MAPEC (Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares [Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events]) study previously reported (2). The study raises some mainly methodological questions and comments: The inclusion criteria regarding status of hypertension are unclear. Were the patients newly diagnosed or known hypertensive patients on treatment? The established goal for clinic blood pressure in diabetes is <130/80 mmHg. Why did the authors consider a daytime blood pressure <135/85 mmHg to be controlled? The authors provide no information on the number and type of antihypertensive medications used at baseline. The randomization procedure to morning or evening drug intake is not described, and it is unclear for the latter group how further randomization to awakening or bedtime treatment was done “separately for each allowed individual hypertension medication” (1 [Supplementary Data]). How many patients randomized to bedtime intake finally took one, two, or three drugs at bedtime? Was the effect on sleep time blood pressure reduction independent of the drug class ingested at bedtime? The 95% CI for event rates in Table 2 and for hazard ratios in Fig. 2 are missing. The association between final asleep blood pressure quintiles and hazard ratio for CVD events in the total study population (Fig. 2) may reflect reverse causality; i.e., patients with low sleep blood pressure have less advanced diabetes complications including less autonomic neuropathy and consequently a good prognosis (3). Have the authors performed a similar analysis for quintiles of baseline asleep blood pressure? Finally we will draw attention to a short term study from another Spanish group (4).
  4 in total

1.  Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects.

Authors:  S Nakano; M Fukuda; F Hotta; T Ito; T Ishii; M Kitazawa; M Nishizawa; T Kigoshi; K Uchida
Journal:  Diabetes       Date:  1998-09       Impact factor: 9.461

2.  Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Chronobiol Int       Date:  2010-09       Impact factor: 2.877

3.  Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

4.  24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.

Authors:  Santiago Tofé Povedano; Bernardo García De La Villa
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-08       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.